J&J's AKEEGA Nears EU Approval for High-Risk Prostate Cancer

BEERSE, Belgium – January 30, 2026 – Johnson & Johnson has moved a significant step closer to introducing a pivotal new treatment for a high-risk group of prostate cancer patients in Europe. The company announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AKEEGA®, a dual-action tablet, for men with metastatic hormone-sensitive prostate cancer (mHSPC) who carry BRCA1 or BRCA2 gene mutations.

This recommendation paves the way for a final decision from the European Commission, typically expected within two months. If approved, AKEEGA® would become the first therapy of its kind for this specific patient population, heralding a new era of precision medicine in the earlier stages of metastatic prostate cancer.

AKEEGA® combines niraparib, a PARP inhibitor, with abiraterone acetate, an established anti-androgen therapy. The treatment is intended to be used alongside prednisone and standard androgen deprivation therapy (ADT). The CHMP's endorsement is based on groundbreaking results from the Phase 3 AMPLITUDE study, which demonstrated that the combination therapy can dramatically delay disease progression in men with these genetic vulnerabilities.

"Patients with metastatic hormone-sensitive prostate cancer who carry BRCA1/2 mutations face a more aggressive disease with survival outcomes that are significantly shorter, compared to those without these mutations, with limited treatment options before their disease progresses to metastatic castration-resistant prostate cancer," said Henar Hevia, Ph.D., Senior Director, EMEA Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine, in a statement. The potential approval signifies a major advancement in addressing this urgent medical need with a targeted strategy.

A Targeted Strike Against Aggressive Disease

The AMPLITUDE study provides compelling evidence for the efficacy of this targeted approach. For men with mHSPC, the presence of a BRCA1/2 mutation—found in roughly one in ten patients with newly diagnosed metastatic disease—is a marker for a more aggressive and difficult-to-treat cancer. These mutations impair the cancer cells' ability to repair their own DNA, a weakness that AKEEGA® is designed to exploit.

The study's results, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, were striking. In the subgroup of patients with BRCA1/2 mutations, treatment with the niraparib and abiraterone acetate combination reduced the risk of radiographic progression or death by an impressive 48 percent compared to the standard-of-care regimen. The median time until the cancer progressed was not even reached in the AKEEGA® group, far surpassing the 26 months observed in the control arm.

Beyond just halting tumor growth, the treatment also significantly delayed the onset of debilitating symptoms. Patients receiving the combination therapy saw a 56 percent reduction in the risk of symptomatic progression. Furthermore, while the data is still maturing, the study revealed an early and encouraging trend toward improved overall survival, with a 25 percent reduction in the risk of death observed in the BRCA-mutated group. Follow-up is ongoing to confirm this survival benefit, which experts view as a highly promising signal.

Redefining the Standard of Care

The potential approval of AKEEGA® for this indication is set to shift the treatment paradigm for prostate cancer. Currently, PARP inhibitors are primarily used in later stages, after the cancer has become resistant to hormone therapy (metastatic castration-resistant prostate cancer, or mCRPC). The AMPLITUDE trial is the first to successfully demonstrate the benefit of this class of drugs in the hormone-sensitive setting for a genetically defined population.

This strategy of early intervention aims to hold the disease at bay for longer, delaying the inevitable and challenging transition to mCRPC. For patients, this could mean more time with a better quality of life before needing more aggressive treatments like chemotherapy.

This development underscores the growing importance of genetic testing in prostate cancer. To identify patients who can benefit from AKEEGA®, oncologists will need to incorporate routine testing for BRCA and other homologous recombination repair (HRR) gene alterations at the time of diagnosis with metastatic disease. According to one independent oncology expert, this approach represents the future of treatment, where combining therapies like niraparib can not only delay cancer recurrence but also "hopefully significantly prolong life expectancy."

Navigating the Clinical and Competitive Landscape

While the efficacy results are robust, the safety profile of the combination therapy requires careful management. Data from the AMPLITUDE study showed that Grade 3 or 4 adverse events occurred in 75% of patients in the niraparib arm, with the most common being anemia and hypertension. These side effects led to dose reductions or treatment discontinuation in a minority of patients but were generally considered manageable with supportive care.

In the competitive landscape of prostate cancer therapeutics, Johnson & Johnson is positioning AKEEGA® as a unique offering. While other PARP inhibitors, such as AstraZeneca's olaparib, are already on the market, AKEEGA®'s key differentiators are its dual-action formulation in a single tablet and its robust data specifically in the mHSPC setting for BRCA-mutated patients. The convenience of a single tablet combining two powerful agents may also offer an advantage in patient adherence.

Johnson & Johnson's Strategic Play in Oncology

This regulatory milestone is a cornerstone of Johnson & Johnson's broader strategy to dominate the prostate cancer market by building a comprehensive and personalized portfolio. The company has explicitly stated that AKEEGA® is designed to complement its existing blockbuster, apalutamide, which is a standard of care for the broader mHSPC population.

By offering apalutamide for the general population and AKEEGA® for the high-risk, BRCA-mutated niche, the pharmaceutical giant can cover a wider spectrum of the patient journey. This two-pronged approach allows for tailored treatment from the outset, maximizing efficacy based on a patient's individual genetic profile.

“The combination of niraparib and abiraterone acetate represents an important step towards integrating targeted precision medicine into routine care, complementing our established apalutamide plus ADT option,” noted Charles Drake, M.D., Ph.D., a Vice President at Johnson & Johnson Innovative Medicine. This strategic positioning reinforces Johnson & Johnson's commitment to delivering solutions across the entire prostate cancer continuum.